Physician profile
Nader Javadi
NPI 1962405266
$27,224.83
in general payments reported to CMS, 2019-2025
76 companies · $5,907 in 2025
The $5,907 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,474 · 2020: $1,243 · 2021: $4,057 · 2022: $4,559 · 2023: $4,530 · 2024: $4,455 · 2025: $5,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Long Term Medical Supply Or Device Loan: $2,030 · Education: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,570.58 |
| Long Term Medical Supply Or Device Loan | $2,029.70 |
| Education | $291.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,334.87 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,368.99 | 2019-2025 | Enhertu, Imfinzi, Tagrisso |
| Incyte Corporation | $1,589.93 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Pfizer INC. | $1,572.05 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,525.45 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $1,400.45 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $1,096.40 | 2019-2025 | Erleada, Rybrevant, Akeega |
| Seagen INC. | $1,003.16 | 2019-2023 | Adcetris, Tivdak, Tukysa |
| Celgene Corporation | $891.49 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Exelixis INC. | $884.04 | 2019-2025 | Cabometyx |
| Amgen INC. | $840.34 | 2019-2025 | Lumakras, Vectibix, Xgeva |
| Glaxosmithkline, LLC. | $634.30 | 2019-2025 | Zejula, Ojjaara, Jemperli |
| Daiichi Sankyo INC. | $625.53 | 2020-2025 | Enhertu, Datroway |
| Lilly USA, LLC | $603.78 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Astellas Pharma US INC | $596.57 | 2019-2025 | Xtandi, Xospata |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Javadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.